



Partnership for
Quality Measurement

Primary Care and Chronic Illness Spring 2023 Measure Review Cycle

Post-Comment Standing Committee Meeting

October 16, 2023

Welcome




Welcome to Today's Meeting!




- Housekeeping reminders:
 - The system will allow you to mute/unmute yourself and turn your video on/off throughout the event
 - Please raise your hand and unmute yourself when called on
 - Please lower your hand and mute yourself following your question/comment
 - Please state your first and last name if you are a Call-In User
 - We encourage you to keep your video on throughout the event
 - Feel free to use the chat feature to communicate with Battelle staff
- If you are experiencing technical issues, please contact the project team via chat on the virtual platform or at PQMsupport@battelle.org.

Using the Zoom Platform



- 1 Click the lower part of your screen to mute/unmute, start, or pause video
- 2 Click on the participant or chat button to access the full participant list or the chat box
- 3 To raise your hand, select the raised hand function under the reactions tab

Using the Zoom Platform (Phone View)




- 1 Click the lower part of your screen to mute/unmute, start or pause video
- 2 Click on the participant button to view the full participant list
- 3 Click on “more” button to (3A) view the chat box, (3B) show closed captions, or to (3C) raise your hand. To raise your hand, select the raised hand function under the reactions tab



3B

3C



Meeting Ground Rules



- Be prepared, having reviewed the meeting materials beforehand
- Respect all voices
- Remain engaged and actively participate
- Base your evaluation and recommendations on the measure evaluation criteria and guidance
- Keep your comments concise and focused
- Be respectful and allow others to contribute
- Share your experiences
- Learn from others

Agenda



- Welcome and Review of Meeting Objectives
- Roll Call
- Voting Test
- Consideration of the Consensus Not Reached Measure and Comments Received
- Related and Competing Measures
- Opportunity for Public Comment
- Next Steps
- Adjourn

Project Team – Prevention & Population Health Committee



- Nicole Brennan, MPH, DrPH, Executive Director
- Brenna Rabel, MPH, Deputy Director
- Quintella Bester, PMP, Senior Program Manager
- Matthew Pickering, PharmD, Principal Quality Measure Scientist
- Lydia Stewart-Artz, PhD, Social Scientist III
- Isaac Sakyi, MSGH, Social Scientist III
- Jessica Ortiz, MA, Social Scientist II
- Elena Hughes, MS, Social Scientist I

Primary Care and Chronic Illness Spring 2023 Cycle Standing Committee



- Dale Bratzler, DO, MPH (Co-Chair)
- Adam Thompson, BA (Co-chair)
- Carlos Bagley, MD, FAANS
- Lindsay Botsford, MD
- William Curry, MD
- Kim Elliott, PhD
- William Glomb, MD, FCCP, FAAP
- James Mitchell Harris, PhD
- Starlin Haydon-Greatting, MS-MPH, BSPHarm, CDM, FAPha
- Ann E Kearns, MD, PhD

- Grace Lee, MD
- Anna McCollister
- Brooke Parish, MD
- James Rosenzweig, MD

Renal Standing Committee Members:

- Lorien Dalrymple, MD, MPH
- Renee Garrick, MD, FACP
- Alan Kliger, MD

Patient Experience and Function Committee Member:

- Christopher Dezii, MBA, RN, CPHQ

Spring 2023 Cycle Measures



- **6 Measures were reviewed**

- **Measures Recommended for Endorsement**

- *#3210e HIV Viral Suppression (Health Resources and Services Administration [HRSA] - HIV/AIDS Bureau)*
- *#3752e HIV Annual Retention in Care (HRSA - HIV/AIDS Bureau)*

- **Consensus Not Reached Measure**

- *#3755e STI Testing for People with HIV (HRSA - HIV/AIDS Bureau)*

- **Measures Not Recommended for Endorsement**

- *#3742 ESRD Dialysis Patient Life Goals Survey (PaLS) (Centers for Medicare & Medicaid Services [CMS]/University of Michigan Kidney Epidemiology and Cost Center)*
- *#3753 Delay in Progression of Chronic Kidney Disease (CKD) Measure (CMS/Yale New Haven Health Services Corporation – Center for Outcomes Research and Evaluation [Yale CORE])*
- *#3754 Risk Standardized Mortality Ratio for Late-Stage Chronic Kidney Disease (CKD) and End Stage Renal Disease (ESRD) (CMS/Yale CORE)*

Voting Test



Consideration of the CNR Measure and Comments Received

Screenshare Post-comment Memo



Related and Competing Measures



Related and Competing Measures



If a measure meets the four criteria **and** there are endorsed/new related measures (same measure focus **or** same target population) or competing measures (both the same measure focus **and** same target population), the measures are compared to address harmonization and/or selection of the best measure.

Target Population	Same concepts for measure focus-target process, condition, event, outcome	Different concepts for measure focus-target process, condition, event, outcome
Same target population	Competing measures - Select best measure from competing measures or justify endorsement of additional measure(s).	Related measures - Harmonize on target patient population or justify differences.
Different target patient population	Related measures - Combine into one measure with expanded target patient population or justify why different harmonized measures are needed.	Neither a harmonization nor competing measure issue

Related and Competing Measures (continued, 1)



- Related and competing measures will be grouped and discussed after the recommendations for all related and competing measures are determined. Only measures recommended for endorsement will be discussed.
- The standing committee can discuss harmonization and make recommendations. The developers of each related and competing measure will be encouraged to attend any discussion.

#3210e - HIV viral suppression Related Measures



- Related Measures
 - #3209e: HIV Medical Visit Frequency
 - #3211e: Prescription of HIV Antiretroviral Therapy
 - #0409: HIV/AIDS: Sexually Transmitted Diseases- Screening for Chlamydia, Gonorrhea, and Syphilis
 - #2080: Gap in HIV medical visits
 - #0405: HIV/AIDS: Pneumocystis Jiroveci Pneumonia (PCP) Prophylaxis

#3210e - HIV viral suppression Related Measure (continued, 1)



- **#3209e HIV Medical Visit Frequency**

- Percentage of patients, regardless of age, with a diagnosis of HIV who had at least one medical visit in each 6-month period within 24 months with a minimum of 60 days between medical visits.
- Numerator: Patients who had at least one medical visit in each 6-month of a consecutive 24-month period with a minimum of 60 days between first medical visit in the prior 6-month period and the last medical visit in the subsequent 6-month period.
- Denominator: Patients, regardless of age, diagnosed with HIV during the first 3 months of the year preceding the measurement period or prior to the measurement period with at least one medical visit in the first 6 months of the year preceding the measurement period.

#3210e - HIV viral suppression Related Measure (continued, 2)



- #3211e Prescription of HIV Antiretroviral Therapy
 - Percentage of patients, regardless of age, with a diagnosis of HIV prescribed antiretroviral therapy for the treatment of HIV infection during the measurement year.
 - Numerator: Number of patients from the denominator prescribed HIV antiretroviral therapy during the measurement year.
 - Denominator: Number of patients, regardless of age, with a diagnosis of HIV with at least one medical visit in the measurement year.

#3210e - HIV viral suppression Related Measure (continued, 3)



- **#0409 HIV/AIDS: Sexually Transmitted Diseases - Screening for Chlamydia, Gonorrhea, and Syphilis**
 - Percentage of patients aged 13 years and older with a diagnosis of HIV/AIDS, who have received chlamydia, gonorrhea, and syphilis screenings at least once since the diagnosis of HIV infection.
 - Numerator: Patients who have received chlamydia, gonorrhea, and syphilis screenings at least once since the diagnosis of HIV infection.
 - Denominator: All patients aged 13 years and older with a diagnosis of HIV/AIDS, who had at least two visits during the measurement year, with at least 90 days between visits.

#3210e - HIV viral suppression Related Measure (continued, 4)



- **#2080 Gap in HIV Medical Visits**

- Percentage of patients, regardless of age, with a diagnosis of HIV who did not have a medical visit in the last 6 months of the measurement year.
- Numerator: Number of patients in the denominator who did not have a medical visit in the last 6 months of the measurement year (Measurement year is a consecutive 12-month period).
- Denominator: Number of patients, regardless of age, with a diagnosis of HIV who had at least one medical visit in the first 6 months of the measurement year. (The measurement year can be any consecutive 12-month period.)

#3210e - HIV viral suppression Related Measure (continued, 5)



- **#0405 HIV/AIDS: Pneumocystis Jiroveci Pneumonia (PCP) Prophylaxis**

- Percentage of patients aged 6 weeks or older with a diagnosis of HIV/AIDS, who were prescribed Pneumocystis jiroveci pneumonia (PCP) prophylaxis.
- Numerator(s):
 - Numerator 1: Patients who were prescribed Pneumocystis jiroveci pneumonia (PCP) prophylaxis within 3 months of CD4 count below 200 cells/mm³
 - Numerator 2: Patients who were prescribed Pneumocystis jiroveci pneumonia (PCP) prophylaxis within 3 months of CD4 count below 500 cells/mm³ or a CD4 percentage below 15%
 - Numerator 3: Patients who were prescribed Pneumocystis jiroveci pneumonia (PCP) prophylaxis at the time of HIV diagnosis.
- Denominator(s):
 - Denominator 1: All patients aged 6 years and older with a diagnosis of HIV/AIDS and a CD4 count below 200 cells/mm³, who had at least two visits during the measurement year, with at least 90 days in between each visit; and,
 - Denominator 2: All patients aged 1 through 5 years of age with a diagnosis of HIV/AIDS and a CD4 count below 500 cells/mm³ or a CD4 percentage below 15%, who had at least two visits during the measurement year, with at least 90 days in between each visit; and,
 - Denominator 3: All patients aged 6 weeks through 12 months with a diagnosis of HIV, who had at least two visits during the measurement year, with at least 90 days in between each visit.

#3210e - HIV viral suppression Related Measures Discussion



- Are the measure specifications for the related measure harmonized to the extent possible?
- Are there differences that could impact interpretability and add data collection burden?
- Are the differences justified?

#3752e - HIV Annual Retention in Care Related Measures



- Related Measures:
 - #3209e: HIV Medical Visit Frequency
 - #3210e: HIV Viral Load Suppression
 - #3211e: Prescription of HIV Antiretroviral Therapy
 - #0409: HIV/AIDS: Sexually Transmitted Diseases- Screening for Chlamydia, Gonorrhea, and Syphilis

#3752e - HIV Annual Retention in Care Related Measure (continued, 1)



- **#3209e HIV Medical Visit Frequency**

- Percentage of patients, regardless of age, with a diagnosis of HIV who had at least one medical visit in each 6-month period within 24 months with a minimum of 60 days between medical visits.
- Numerator: Patients who had at least one medical visit in each 6-month of a consecutive 24-month period with a minimum of 60 days between first medical visit in the prior 6-month period and the last medical visit in the subsequent 6-month period.
- Denominator: Patients, regardless of age, diagnosed with HIV during the first 3 months of the year preceding the measurement period or prior to the measurement period with at least one medical visit in the first 6 months of the year preceding the measurement period.

#3752e - HIV Annual Retention in Care Related Measure (continued, 2)



- **#3210e HIV Viral Load Suppression**

- Percentage of patients, regardless of age, with a diagnosis of HIV with a HIV viral load less than 200 copies/mL at last HIV viral load test during the measurement year.
- Numerator: Patients with a HIV viral load less than 200 copies/mL at last HIV viral load test during the measurement year. The outcome being measured is HIV viral suppression.
- Denominator: Patients, regardless of age, diagnosed with HIV during the first 3 months of the measurement year or prior to the measurement year who had at least one medical visit in the measurement year. The target population for this measure is all people living with HIV.

#3752e - HIV Annual Retention in Care Related Measure (continued, 3)



- **#3211e Prescription of HIV Antiretroviral Therapy**

- Percentage of patients, regardless of age, with a diagnosis of HIV prescribed antiretroviral therapy for the treatment of HIV infection during the measurement year.
- Numerator: Number of patients from the denominator prescribed HIV antiretroviral therapy during the measurement year.
- Denominator: Number of patients, regardless of age, with a diagnosis of HIV with at least one medical visit in the measurement year.

#3752e - HIV Annual Retention in Care Related Measures (continued, 4)



- **#0409 HIV/AIDS: Sexually Transmitted Diseases- Screening for Chlamydia, Gonorrhea, and Syphilis**
 - Percentage of patients aged 13 years and older with a diagnosis of HIV/AIDS, who have received chlamydia, gonorrhea, and syphilis screenings at least once since the diagnosis of HIV infection.
 - Numerator: Patients who have received chlamydia, gonorrhea, and syphilis screenings at least once since the diagnosis of HIV infection.
 - Denominator: All patients aged 13 years and older with a diagnosis of HIV/AIDS, who had at least two visits during the measurement year, with at least 90 days between visits.

#3752e - HIV Annual Retention in Care Related Measures Discussion



- Are the measure specifications for the related measure harmonized to the extent possible?
- Are there differences that could impact interpretability and add data collection burden?
- Are the differences justified?

#3755e - STI Testing for People with HIV Related Measures



- Related Measures
 - #3209e HIV Medical Visit Frequency
 - #3210e HIV Viral Load Suppression
 - #3211e Prescription of HIV Antiretroviral Therapy
 - #0409 HIV/AIDS: Sexually Transmitted Diseases- Screening for Chlamydia, Gonorrhea, and Syphilis

#3755e - STI Testing for People with HIV Related Measures (continued, 1)



- **#3209e HIV Medical Visit Frequency**

- Percentage of patients, regardless of age, with a diagnosis of HIV who had at least one medical visit in each 6-month period within 24 months with a minimum of 60 days between medical visits.
- Numerator: Patients who had at least one medical visit in each 6-month of a consecutive 24-month period with a minimum of 60 days between first medical visit in the prior 6-month period and the last medical visit in the subsequent 6-month period.
- Denominator: Patients, regardless of age, diagnosed with HIV during the first 3 months of the year preceding the measurement period or prior to the measurement period with at least one medical visit in the first 6 months of the year preceding the measurement period.

#3755e - STI Testing for People with HIV Related Measures (continued, 2)



- **#3210e HIV Viral Load Suppression**

- Percentage of patients, regardless of age, with a diagnosis of HIV with a HIV viral load less than 200 copies/mL at last HIV viral load test during the measurement year.
- Numerator: Patients with a HIV viral load less than 200 copies/mL at last HIV viral load test during the measurement year. The outcome being measured is HIV viral suppression.
- Denominator: Patients, regardless of age, diagnosed with HIV during the first 3 months of the measurement year or prior to the measurement year who had at least one medical visit in the measurement year. The target population for this measure is all people living with HIV.

#3755e - STI Testing for People with HIV Related Measures (continued, 3)



- **#3211e Prescription of HIV Antiretroviral Therapy**

- Percentage of patients, regardless of age, with a diagnosis of HIV prescribed antiretroviral therapy for the treatment of HIV infection during the measurement year.
- Numerator: Number of patients from the denominator prescribed HIV antiretroviral therapy during the measurement year.
- Denominator: Number of patients, regardless of age, with a diagnosis of HIV with at least one medical visit in the measurement year.

#3755e - STI Testing for People with HIV Related Measures (continued, 4)



- **#0409 HIV/AIDS: Sexually Transmitted Diseases- Screening for Chlamydia, Gonorrhea, and Syphilis**
 - Percentage of patients aged 13 years and older with a diagnosis of HIV/AIDS, who have received chlamydia, gonorrhea, and syphilis screenings at least once since the diagnosis of HIV infection.
 - Numerator: Patients who have received chlamydia, gonorrhea, and syphilis screenings at least once since the diagnosis of HIV infection.
 - Denominator: All patients aged 13 years and older with a diagnosis of HIV/AIDS, who had at least two visits during the measurement year, with at least 90 days between visits.

#3755e - STI Testing for People with HIV Related Measures Discussion



- Are the measure specifications for the related measure harmonized to the extent possible?
- Are there differences that could impact interpretability and add data collection burden?
- Are the differences justified?

Opportunity for Public Comment



Next Steps



Activities and Timeline – Spring 2023 Cycle



Meeting	Date, Time*
Consensus Standards Approval Committee (CSAC) Review	December 6, 10am – 5pm and December 7, 10am – 2pm
Appeals Period (30 days)	December 9 – January 7

- Battelle staff will incorporate the developer’s comment and the committee’s response to the comment into meeting materials for the Consensus Standards Approval Committee (CSAC) meeting
- CSAC meets to endorse measures
- Opportunity for public to appeal endorsement decision

* All times are Eastern

Thank You!

Have questions? Contact us at
PQMsupport@battelle.org





Partnership for
Quality Measurement

powered by

BATTELLE